The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Compound

semaglutide

GLP-1 receptor agonist; the compound with the largest published human dataset in this class.

80 topics 17 solved Synonyms: sema Group: Compound

Related in this group: tirzepatide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues

80 topics · page 2 of 3

TopicParticipantsRepliesViewsActivity
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…
KBDBVBNTIG+128 145 3k 4mo
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
MBHVSKKLCL+24 28 51k 5mo
How the published trials escalated, tabulated side by side
The question in the title: How the published trials escalated, tabulated side by side I will give what I have already checked below so nobody repeats it. A question about technique rather than about dose. I…
ASCTGAOFCC+4 8 4.2k 5mo
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…
SKBOSBBDAL+42 46 1.7k 5mo
The lowest dose that does anything: is that a real question?
Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question? I have read the maintained page on this and I still have a gap, so I am asking rather…
PPDFPGDVS+100 111 9.1k 5mo
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
MMLIYR 2 63k 5mo
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…
CNACSE 2 1.9k 5mo
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
WVERFYWMB+124 133 11k 5mo
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet ,…
VSFVSC 2 39k 6mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…
LRAAEVDMA+57 63 1k 6mo
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
AMHNDNLAMD+5 9 21k 7mo
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…
SRMAETPOAR+6 10 6.1k 8mo
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still have a…
KDEJMSKP+127 137 32k 8mo
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
KTVSMNARF 4 32k 8mo
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…
CRRWMHKMN+86 90 61k 9mo
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
SGBCTNNATT+22 26 1.8k 9mo
Dose numbers across compounds are not on the same scale
Dose numbers across compounds are not on the same scale — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking…
BPISC 2 1.6k 9mo
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept Reporting something rather than asking about it, in case the pattern…
BWSANTIRSS+7 11 26k 9mo
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
HCFPNVBICM 4 9.9k 10mo
Washout: how long is long enough, and for what purpose
Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in…
BBNKPABRE+63 70 13k 10mo
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…
ACQZES 2 867 10mo
Escalating every six weeks instead of four: what I observed over eight months — one year on
On the subject in the title: Escalating every six weeks instead of four: what I observed over eight months — one year on Working notes rather than a conclusion. I have read the maintained page on this and I…
KHMPLSEVLP+55 59 9.1k 10mo
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
ISSSAKIR+35 39 547 11mo
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
AKTLAW 2 136 11mo
About the Semaglutide category
GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
TVJMRJGOMH 4 4.2k 11mo
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
ICNTLMSO+112 119 3.3k 11mo
Subcutaneous absorption kinetics and site differences
Posting this under the heading it deserves: Subcutaneous absorption kinetics and site differences Everything below is what sits behind that. I would like to understand what this number means before I repeat…
NRVRMRNSS+15 19 3.9k 12mo
Holding a dose indefinitely: is there a documented downside?
Holding a dose indefinitely: is there a documented downside? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I have…
HFOBRSPPBD+28 32 57k 12mo
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
POCCMH 2 31k 13mo
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
KRBSKSBCD+5 9 44k 13mo